Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study

Inclusion Criteria: * Diagnosis of mCRPC and bone metastases * ≥ 40 years of age at diagnosis of mCRPC * Initiated first line treatment for mCRPC with abi/enza (use of sipuleucel-T prior to initiation of abi or enza is allowed) * Receipt of at least one cycle of radium-223 after 15 May 2013 * First cycle of Ra-223 occurs while receiving first line treatment with abi/enza * Treated with abi/enza for at least 28 days (1 cycle) following initiation of Ra-223 * Initiation of Ra-223 at least 6 months after the start of treatment with abi/enza * Completion of Ra-223 treatment prior to the receipt of any chemotherapy for mCRPC * At least 12 months of follow-up (or until death) from date of initiation of Ra-223 * Known date of death (if patient deceased) Exclusion Criteria: * Receipt of any prior chemotherapy during hormone sensitive disease or any time before mCPRC * Active participant in an interventional clinical trial for CRPC in first line * Presence of visceral metastases at initiation of Ra-223 treatment * Treated with abi/enza (with or without docetaxel) prior to the development of metastatic and/or castration resistant disease